FDA
-
-
-
-
-
-
-
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
-
-
-
-
-
-
-
Eton Pharmaceuticals acquires HEMANGEOL commercialization rights
-
-
-
-
-
-
-
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
-
-
-
-
-
-
-
Eton Pharmaceuticals (ETON) Announces Extension of PDUFA Goal Date for ET-400
-
-
-
-
-
-
-
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
-
-
-
-
-
-
-
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
-
327,645 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

